The aggressive colorectal cancer subtype marker HTR2B has a dual role depending on the tumor microenvironment.

ABSTRACT: Colorectal cancer (CRC) is the second-third most frequent cancer type in the Western countries, with significant inter- and intra-patient cellular heterogeneity. The transcriptomics-based CRC classification identified a cluster of patients with epithelial-mesenchymal transition (EMT), the accumulation of fibroblasts, and dismal prognosis. Although the serotonin receptor HTR2B is thought to be one of the epithelial markers of this aggressive CMS4 subgroup, its precise role in CRC tumorigenesis is still largely unknown. By using patient-derived organoids (PDO), we prove the heterogeneous expression of this receptor that is under the control of the mTOR pathway. Unfavorable conditions, applying the clinically used 5-fluorouracil, co-culturing with fibroblasts, and collagen-I accumulation in t

SUBMITTER: Carmi I 

PROVIDER: S-EPMC12486794 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature